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for prophylactic and therapeutic vaccination to combat infec-
tious diseases or cancer. In the past years, optimization of the
characteristics of in vitro transcribed mRNA has led to signifi-
cant reduction of the inflammatory responses. Thanks to this,
mRNA therapeutics have entered the field of passive immuni-
zation. Here, we established an mRNA treatment that is based
on mRNA that codes for a bispecific single-domain antibody
construct that can selectively recruit innate immune cells to
cells infected with influenza A virus. The constructs consist
of a single-domain antibody that binds to the ectodomain of
the conserved influenza Amatrix protein 2, while the other sin-
gle-domain antibody binds to the activating mouse Fcg recep-
tor IV. Formulating the mRNA into DOTAP (1,2-dioleoyl-3-
trimethylammonium-propane)/cholesterol nanoparticles and
delivering these intratracheally to mice allowed the production
of the bispecific single-domain antibody in the lungs, and
administration of these mRNA-particles prior to influenza A
virus infection was associated with a significant reduction in
viral titers and a reduced morbidity in mice. Overall, our
data provide evidence that the local delivery ofmRNA encoding
a bispecific single-domain antibody format in the lungs could
be a promising pulmonary antiviral prophylactic treatment.Received 18 February 2020; accepted 27 April 2020;
https://doi.org/10.1016/j.omtn.2020.04.015.
Correspondence: Xavier Saelens, VIB-UGent Center for Medical Biotechnology,
VIB, 9000 Ghent, Belgium.
E-mail: xavier.saelens@vib-ugent.beINTRODUCTION
In the nineties, Wolff et al.1 showed that exogenous transcribed
mRNA can be used to express proteins in vivo. However, only in
recent years, mRNA has emerged as a promising drug platform tech-
nology. So far, in vitro transcribed (IVT) mRNA has shown its utility
as a vaccine format in cancer immunotherapy2–5 and as a tool to pro-
mote prophylactic protection against infectious diseases.5–10 A num-
ber of modifications to the vector used to produce the mRNA, as well
as to the synthetic mRNA itself, have further ameliorated the biologic
properties of the IVTmRNA. For example, modified nucleotides such
as N1-methylpseudouridine (N1mJ) are used to decrease inappro-
priate stimulation of cellular RNA sensors and, thus, to avoid a strongMolecular T
This is an open access article under the CC BY-NC-induction of pro-inflammatory cytokine secretion. As the potency
and safety of mRNA treatments grew, other fields of application for
mRNA-based biologics became accessible. These include the applica-
tion of mRNA encoding different antibody formats to protect against
different viral, bacterial, or malignant diseases.11–14
The use of mRNA for passive immunization has several benefits
compared to the use of recombinant proteins. For instance, mRNA
is produced in cell-free circumstances and because it consists of
only four building blocks, it has uniform physicochemical properties.
These characteristics enable a safe and generic production and puri-
fication process, potentially reducing the costs compared to a protein-
based approach. Additionally, mRNA can give rise to protein expres-
sion for a few days, leading to prolonged and higher peak titers of the
antibody format in circulation compared with the protein format.
This is of interest as it entails that with mRNA the frequency of
dose administration could be reduced. On top, monoclonal anti-
bodies are prone to a wide variety of post-translational modifications,
including glycosylation, deamidation, oxidation, incomplete disulfide
bond formation, N-terminal glutamine cyclization, and C-terminal
lysine processing. The use of mRNA encoding antibodies allows for
the in situ production of the biologics in the body itself. Also, prob-
lems of purification and heterogeneity of the end product can be
circumvented.
Single domain antibodies (VHHs, also known as nanobodies),
derived from the variable domain of heavy-chain-only antibodies
found in camelids, have been used inmany therapeutic applications.15
Recently, our group developed a novel anti-influenza A virus strategy
based on an engineered bispecific VHH construct that is able to selec-
tively recruit innate immune cells to influenza A virus-infected cells.16herapy: Nucleic Acids Vol. 20 June 2020 ª 2020 The Author(s). 777
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. In Vitro Characterization of mRNA
Encoded Bispecific VHH Constructs
(A) Design of mRNA encoding the bispecific VHH con-
structs (RiboBiFEs). The two VHHs that are genetically
linked by means of a flexible 15 amino acid residues
long (Gly4Ser)3 linker are directed to the secretory
pathway by a secretion signal derived from the murine
Ig heavy chain V region BCL1 precursor. The VHH
fusion constructs also contain a His6-tag at the car-
boxy-terminus. Two types of RiboBiFEs were con-
structed: M2e VHH linked to FcgRIV VHH or RSVF VHH
(directed against the fusion protein of respiratory syn-
cytial virus) linked to FcgRIV VHH. (B) Immunoblot
detection with a His6-tag-specific horseradish peroxi-
dase (HRP)-conjugated antibody of the medium fraction
of mRNA transfected HEK293T cells. HEK293T cells
were transfected with 10 mg of IVT mRNA coding for
the indicated His6-tagged RiboBiFEs. 48 h later,
one tenth of the trichloroacetic acid precipitated su-
pernatant was analyzed by non-reducing western
blot analysis. (C) The ability of the mRNA encoding FcgRIV VHH-M2e VHH and the FcgRIV VHH-RSVF VHH to bind to M2e was investigated in an M2e peptide
ELISA. Supernatants from HEK293T cells 48 h after transfection with mRNA encoding the RiboBiFEs were used.
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moderate affinity to the conserved influenza A matrix protein 2 ecto-
domain (M2e) to a VHH that specifically binds to the mouse Fcg re-
ceptor IV (FcgRIV). By administering these bispecific VHH anti-
bodies 4 h before and 20 h after influenza A virus infection,
morbidity caused by an influenza A virus challenge could be signifi-
cantly lowered. The M2e is chosen as a target as it is highly conserved
among different influenza A subtypes, and different murine studies
have shown that M2e-based vaccines can induce a broad protection
that is antibody mediated.17–19 It is shown that alveolar macrophages
are the main cell types that are responsible for protection by anti-M2e
antibodies.20 M2 is expressed on the surface of cells infected with
influenza A virus. Therapeutic administration of a human M2e-spe-
cific immunoglobulin G1 (IgG1) monoclonal antibody was associated
with reduced symptoms compared with placebo treatment in a
controlled human influenza virus challenge model.21,22 FcgRs are ex-
pressed on different innate immune cells like macrophages, neutro-
phils, natural killer cells, and dendritic cells.23,24
Here, we propose the use of in vitro transcribed nucleoside-modified
mRNA coding for the engineered bispecific VHH construct. We
generated N1-methylpseudouridine-containing mRNAs encoding
His-tagged bispecific VHH (RiboBiFE; bispecific Fc-receptor
engaging) of which one part is directed against M2e and the other
part against the mouse FcgRIV. For the pulmonary delivery of the
RiboBiFE constructs, the low-immunogenic nucleoside-modified
mRNA was formulated in a liposomal formulation composed of the
cationic lipid DOTAP (1,2-dioleoyl-3-trimethylammonium-pro-
pane) and cholesterol. We found that the intratracheal (i.t.) adminis-
tration of mRNA-DOTAP/cholesterol nanoparticles in mice resulted
in an expression of the bispecific VHH construct in the lungs, with
detectable protein expression levels for at least 2 days. Furthermore,
with a single shot of mRNA-nanoparticles encoding the RiboBiFE778 Molecular Therapy: Nucleic Acids Vol. 20 June 2020construct before an influenza A virus challenge, we could significantly
lower morbidity and pulmonary virus titers. These findings further
underline the merit of mRNA-based strategies in passive immuniza-
tion settings.
RESULTS
Design and In Vitro Characterization of RiboBiFEs
Here, we designed a mRNA-treatment based on the recent report of
De Vlieger et al.16 on a protein bispecific VHH fusion construct con-
sisting of a VHH moiety selectively binding to the activating mouse
FcgRIV and another VHH moiety that binds to the conserved influ-
enza AM2e domain. A flexible 15 amino acid residues long (Gly4Ser)3
linker was used to genetically fuse the two VHH moieties. Upstream
of the VHHs a secretion signal derived from the Ig heavy chain V re-
gion BCL1 precursor was added and an His6-tag was included at the
carboxy-terminus. To increase translation efficiency and half-life of
the mRNA, we flanked the coding sequence by optimized untrans-
lated regions (UTRs). From this construct we generated N1-methyl-
pseudouridine (m1J)-containing mRNAs encoding the bispecific
VHH constructs, which we termed RiboBiFEs (Figure 1A). As a nega-
tive control, RiboBiFEs comprising the FcgRIV-VHH linked to a
VHH directed against the respiratory syncytial virus fusion protein
(FcgRIV VHH-RSVF VHH) were constructed.
The expression of intact in vitro transcribed (IVT) RiboBiFEs was
confirmed by a western blot analysis on the trichloroacetic acid
precipitated supernatant of HEK293T cells transfected with the
RiboBiFEs (Figure 1B). Next, we evaluated whether the in situ pro-
duced protein derived from the RiboBiFE-format is still able to
bind to its M2e target as reported by De Vlieger et al.16 Using an
M2e peptide enzyme-linked immunosorbent assay (ELISA), we
confirmed the ability of the FcgRIV VHH-M2e VHH RiboBiFE to
bind to its M2e target (Figure 1C).
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DOTAP/Cholesterol Nanoparticles
In previous reports by Verbeke et al.,25,26 mRNA nanoparticles
composed of DOTAP and cholesterol were developed and character-
ized for the systemic delivery of mRNA vaccines. Due to electrostatic
interactions, cationic DOTAP/cholesterol liposomes form complexes
with negatively charged mRNA, protecting the mRNA cargo from
degradation and holding stable transfection efficiencies in vivo. To
obtain an efficient mRNA expression of the RiboBiFE construct at
the viral entry site, we investigated in this study whether we could
use this lipid formulation for the pulmonary delivery of mRNA via
i.t. instillation.
The positively charged mRNA nanoparticles are expected to interact
with noncellular components present in the lungs, such as phospho-
lipids and proteins, which may affect physicochemical and functional
properties of the nanoformulation. Therefore, we first analyzed the
colloidal stability of the mRNA nanoparticles in bronchoalveolar
lavage fluid (BALF). After 1 h incubation in BALF, the mRNA nano-
particles displayed a 1.85-fold increase in size going from 183 nm to
339 nm, indicating a reduction in colloidal stability in presence of bio-
molecular lung content.
Next, we evaluated the mRNA delivery efficiency in BALB/c mice af-
ter i.t. administration of mRNA nanoparticles, using different re-
porter mRNAs, as well by the inclusion of a lipophilic, near-infrared
fluorescent dye DiR inside the liposome formulation. In a first exper-
iment, mice were instilled with DOTAP/cholesterol particles contain-
ing 5 mg of luciferase reporter mRNA. 6 h post administration, a se-
lective and evenly distributed luciferase expression, was detected in
the lungs (Figure 2B). In a second experiment, mice were adminis-
tered with nanoparticles containing both DiR dye and mCherry re-
porter mRNA. These mRNA nanoparticles allowed us to identify
which pulmonary cell types were involved in the uptake of mRNA
particles, as well as to evaluate the mRNA translation in each cell
type. For this, transfected lungs of mice were collected at 6 h or
24 h post administration, and the different pulmonary cells subsets
were analyzed by flow cytometry for the presence of DiR signal and
mCherry expression. At 6 h, nanoparticle uptake was detected in
CD45+ immune cells with a percentage of 3.5% ± 1.7% nanopar-
ticle-positive cells, which increased up to 5.3% ± 2.3% by 24 h (Fig-
ure 2C). In contrast, almost no DiR signal was detected in the
CD45 (nonimmune) cell population (0.12% ± 0.06%). When look-
ing in more detail at the cellular uptake in pulmonary immune cell
subsets, it appeared that alveolar macrophages were primarily respon-
sible for the clearance of the particles, with a percentage of 43.8% ±
24.8% nanoparticle-positive alveolar macrophages at 6 h and
65.5% ± 27.3% at 24 h. There were no significant levels of DiR signal
detected in the other cell subsets (Figure 2D). With respect to the
expression of mCherry mRNA, we found a cell-specific mRNA trans-
lation in alveolar macrophages with a transfection efficiency of
19.9% ± 10.9% mCherry-positive cells at 6 h and 31.5% ± 17.9% at
24 h (Figure 2E). Finally, to determine the kinetics and durability spe-
cific for the expression of the therapeutic mRNA construct, a singledose of mRNA particles composed with the FcgRIV VHH-M2e
VHH RiboBiFE construct was delivered i.t. to the lungs of BALB/c
mice. BALF was taken 6, 24, or 48 h after i.t. instillation. Using
M2e-peptide ELISA, the highest expression was seen 6 h post admin-
istration followed by a gradual decrease but retaining detectable levels
up to 48 h after instillation (Figure 2F; Figure S2). We compared the
absolute antibody titers after injection of the mRNA-particles with
the antibody titers obtained after i.t. instillation of 50 mg of the bispe-
cific FcgRIV VHH-M2e VHH fusion protein as performed by De
Vlieger et al.16 BALF was taken 24 or 48 h after i.t. instillation and ab-
solute titer was determined. Only 24 h after instillation of the bispe-
cific protein, antibody titers above the detection limit were detected
(Figure 2F; Figure S2).
Taken together, these results demonstrate that the i.t. administration
of DOTAP/cholesterol mRNA nanoparticles can achieve a local and
durable expression of the (RiboBiFE) mRNA in the lungs, with a
cell specific uptake and mRNA translation by alveolar macrophages.
Acute Inflammatory Responses to i.t. Instilled mRNA
Nanoparticles
In the mice that were i.t. instilled with the reporter mRNA nanopar-
ticles containing mCherry mRNA and DiR dye, we also screened for
inflammatory responses that may be triggered by the lipid formula-
tion itself, as well as by innate immune reactions to the mRNA cargo.
For this, we first investigated whether the mRNA nanoparticles acti-
vated the recruitment of inflammatory cells to the lungs, which could
indicate the presence of acute lung inflammation. Overall, the infiltra-
tion of CD45+ cells, as well as most of the specific immune cell subsets
that we evaluated, were not subject to changes in their relative abun-
dance in the lung. Only a temporary increase in the levels of granulo-
cytes (gated out as CD11c, MHC-II, CD11b+, CD24+ cells) was
observed, which was restored to baseline values within 24 h (Fig-
ure 3A). In terms of systemic cytokine responses generated by the
i.t. instilled mRNA nanoparticles, we measured a panel of 13 inflam-
matory cytokines and chemokines (Figure 3B). We could detect a
higher concentration of interleukin-6 (IL-6) in the blood samples at
6 h post administration of mRNA nanoparticles, which again re-
turned to baseline by 24 h. Other than for IL-6, no statistically signif-
icant differences were observed for the other investigated cytokines
and chemokines relative to PBS-treated mice.
Evaluation of the Protective Potential of Pulmonary Delivery of
RiboBiFEs in an Influenza A Virus Infection
Previously, De Vlieger et al.16 demonstrated that bispecific FcgRIV
VHH-M2e VHH fusion protein, recombinantly produced in Pichia
pastoris, could protect mice from body weight loss and lethality
caused by an influenza A virus infection when 50 mg of the protein
was administered intranasal 4 h before and 20 h after infection. In
accordance, we investigated the potential of the mRNA encoded
FcgRIV VHH-M2e VHH RiboBiFEs to protect in a similar influenza
challenge model in vivo. To this end, 5 mg m1-J modified mRNA
complexed into DOTAP/cholesterol particles was administered i.t.
4 h before challenge with 2 LD50 of X47 (H3N2) influenza A virus.Molecular Therapy: Nucleic Acids Vol. 20 June 2020 779
Figure 2. Delivery of DOTAP/Cholesterol mRNA Lipid Nanoparticles via Intratracheal Instillation
(A) Particle size analysis after incubating DOTAP/cholesterol mRNA lipoplexes in HEPES buffer or bronchoalveolar lavage fluid (BALF). BALB/c mice were i.t. administered
with DOTAP/cholesterol particles formulated with different mRNA sequences (mRNA dose of 5 mg). (B) Graph and representative whole-body images showing expression
levels of luciferasemRNA (5-methoxyuridine) in lungs of BALB/cmicemeasured via bioluminescence imaging at 6 h (n = 3mice). DOTAP/cholesterol nanoparticles containing
1 mol% of the lipophilic dye DiR and packaged with mCherry mRNA (5-methoxyuridine) were i.t. administered, after which nanoparticle uptake (DiR fluorescence) andmRNA
expression (mCherry protein) were evaluated in a variety of pulmonary cells subsets (n = 5mice) at 6 and 24 h post administration. The flow cytometry gating strategy used to
discriminate between pulmonary immune cell subsets can be found in the Figure S1 and was adopted from Knight et al.45 PBS-instilled mice serve as negative controls. (C)
Graph shows nanoparticle uptake in CD45 positive cells (immune cells) and CD45 negative cells (nonimmune cells). (D) Nanoparticle uptake in a variety of pulmonary immune
cells subsets, including alveolar macrophages, CD103+ dendritic cells (CD103+DCs), granulocytes, other subsets of monocytes and macrophages that are not encom-
passed by the other subsets (Mono/macrophage), interstitial macrophages, and CD11b+ DCs. (E) Representative flow cytometry plots of nanoparticle uptake and mCherry
mRNA expression in alveolar macrophages. The mean percentage of DiR-positive and mCherry-positive cells, together with the mean fluorescence intensity of each signal,
are given in each flow plot. (F) 5 mg of FcgRIV VHH-M2e VHH or FcgRIV VHH-RSVF VHH (irrelevant mRNA) formulated in DOTAP/cholesterol particles or 50 mg FcgRIV VHH-
M2e VHH protein was instilled i.t. in BALB/c mice. 6, 24, or 48 h after instillation, BALF was isolated and cells were removed from the BALF and the ability of His6-tagged
proteins to bind to M2e was investigated in a peptide ELISA (see Figure S2). De absolute titers were calculated using the standard curve shown in Figure S2. Graphs show
mean ± SEM (n = 3 mice per group). Statistical analyses on datasets were performed by one-way ANOVA followed by Tukey’s post hoc test. Asterisks indicate statistical
significance compared to negative control (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
Molecular Therapy: Nucleic Acids
780 Molecular Therapy: Nucleic Acids Vol. 20 June 2020
Figure 3. Inflammatory Response to Intratracheally Administered mRNA Nanoparticles
(A) Graph depicts the relative distribution of each pulmonary immune cell subset as a percent of total viable cells, for PBS-treated mice, and mice that were i.t. instilled with
DiR-labeled mRNA nanoparticles containing mCherry mRNA (mRNA dose of 5 mg), that were either sacrificed at 6 or 24 h post administration (n = 5mice). (B) Serum samples
collected from thesemice were screened for the presence of inflammatory cytokine responses. Statistical analyses on datasets were performed by one-way ANOVA followed
by Tukey’s post hoc test. Asterisks indicate statistical significance compared to negative control (*p < 0.05; ***p < 0.001).
www.moleculartherapy.orgAs controls, mice were treated with PBS or nanoparticles contain-
ing luciferase mRNA or non-influenza targeted FcgRIV VHH-
RSVF VHH mRNA. Body weight change and mortality were moni-
tored daily after virus challenge. Mice that had been treated with
FcgRIV VHH-M2e VHH RiboBiFEs were significantly better pro-
tected from body weight loss and lethality caused by the influenza
virus infection compared to the negative control groups (Figure 4A).
A subset of the treated mice was euthanized on day 6 after
challenge to determine the pulmonary virus titers after treatment
and infection using plaque assay. Analysis showed that the protec-
tion mediated by FcgRIV VHH-M2e VHH RiboBiFE was associ-ated with a statistically significant reduction in lung viral titer
(Figure 4B).
Finally, we verified whether the protection by the FcgRIV VHH-M2e
VHH RiboBiFE was indeed mediated by FcgRIV engagement. For
this, wild-type and FcgRIV/ C57BL/6 mice were i.t. treated with
5 mg of mRNA encoding FcgRIVVHH-M2e VHH or as negative con-
trol mRNA encoding luciferase or FcgRIV VHH-RSVF VHH. 4 h
later, mice were intranasally challenged with 2 LD50 of A/X47
(H3N2) influenza virus. Treatment with mRNA encoding FcgRIV
VHH-M2e VHH was able to protect wild-type mice against theMolecular Therapy: Nucleic Acids Vol. 20 June 2020 781
Figure 4. In Vivo Delivery of Lipid Nanoparticle
Formulated mRNA that Encode FcgRIV VHH-M2e
VHH Protects Mice against a Potentially Lethal
Influenza A Virus Challenge
(A) BALB/c mice were i.t. instilled with PBS or 5 mg mRNA
encoding FcgRIV VHH-M2e VHH, FcgRIV VHH-RSVF
VHH, or luciferase (irrelevant) mRNA formulated in
DOTAP/cholesterol particles. 4 h later, mice were chal-
lenged with 2 LD50 of A/X47 (H3N2) influenza virus.
Body weight change (left) and survival (right) were moni-
tored for 14 days. The mean relative changes in body
weight together with their standard errors are repre-
sented. The survival rate of the group receiving RiboBiFEs
encoding FcgRIV VHH-M2e VHH was significantly
different from the control groups (***p < 0.001, log-rank
test; Bonferroni correction; n = 6 mice). (B) BALB/c mice
were treated as in (A). 6 days after infection, 4 mice from
each group were sacrificed and the lungs were isolated to
determine the viral load by plaque assay. The viral titer of
mice receiving mRNA encoding for FcgRIV VHH-M2e
VHH was significantly different compared to mice that
received the control treatment (***p < 0.001, Kruskal-
Wallis; n = 4mice). (C) C57BL/6 wild-typemice or C57BL/
6 FcgRIV/ mice were i.t. instilled with 5 mg mRNA en-
coding FcgRIV VHH-M2e VHH or FcgRIV VHH-RSVF
VHH formulated in DOTAP/cholesterol particles. 4 h later,
mice were challenged with 2 LD50 of A/X47 (H3N2)
influenza virus. Body weight change (left) and survival
(right) was monitored for 14 days. The mean relative
changes in body weight together with their standard er-
rors are represented. The survival rate of the wild-type
mice receiving RiboBiFE encoding FcgRIV VHH-M2e
VHH was significantly different from wild-type mice
treated with RiboBiFE encoding FcgRIV VHH-RSVF VHH
and FcgRIV/ mice treated with FcgRIV VHH-M2e VHH
and FcgRIV VHH-RSVF VHH RiboBiFEs (**p < 0.001, log-
rank test; Bonferroni correction; n = 5 mice for the group
treated with mRNA encoding FcgRIV VHH-RSVF VHH
and n = 6 for the group treated with mRNA encoding
FcgRIV VHH-M2e VHH).
Molecular Therapy: Nucleic Acidsotherwise lethal influenza challenge while FcgRIV/ mice, whereas
control-treated wild-type and FcgRIV/ mice were not protected
(Figure 4C).
Taken together, these data show that a single prophylactic adminis-
tration of mRNA encoding two-domain construct FcgRIV VHH-
M2e VHH can protect mice against a potentially lethal influenza A
virus challenge by specifically employing the mouse FcgRIV.
DISCUSSION
Previously, De Vlieger et al.16 engineered a bispecific VHH fusion
protein that selectively binds to and activates FcgRIV present on
innate immune cells with one moiety and binds to M2e present
on influenza A virus infected cells with the other moiety. Here,782 Molecular Therapy: Nucleic Acids Vol. 20 June 2020we added onto the findings reported by De Vlieger et al.16 by
formulating mRNA encoding the bispecific VHH fusion proteins,
termed RiboBiFEs, into DOTAP/cholesterol particles. Through i.t.
instillation of the mRNA-DOTAP/cholesterol particles, the bispe-
cific VHH fusion proteins were produced in situ in the lungs, the
specific site of virus infection in the murine influenza model, for
a prolonged period of time as shown by ELISA on the BALF. We
showed that i.t. administration of a single shot of RiboBiFEs 4 h
before challenge with 2 LD50 of A/X47 (H3N2) influenza virus
protects mice from excessive body weight loss and lethality caused
by influenza virus infection. Furthermore, we confirmed the
involvement of FcgRIV engagement in the protection mediated
by the RiboBiFEs. A notable improvement of the formulated
mRNA delivery over the protein-based bi-specific VHH constructs
www.moleculartherapy.orgis the prolonged availability of the protective biologic in the lung
compartment.
The most popular antibody-formats used in the clinic are full-size Igs
of the IgG isotypes. These antibodies are produced mainly in
mammalian cells since the heterotetramerical structure of such full-
size Igs requires correct disulfide bridge formation and glycosylation
for proper functioning.27,28 Nearly 30 years ago also variable domain
fragments of heavy-chain-only (VHH) Ab fragments were discov-
ered. These VHHs are derived from heavy-chain-only antibodies of
camelids and sharks and lack light chains.29,30 Antibody fragments
are also the basis of bispecific VHH that today form a huge family
comprising a multitude of different formats.31–34 Advantages of
VHHs over conventional antibody formats are their outstanding sol-
ubility, stability, and excellent tissue penetration capacities. More-
over, due to their single-domain structure these VHHs can be easily
formatted. Moreover, bispecific VHH are formed from a single
construct. In contrast, two constructs are needed for a full-size Ab,
one for the heavy chain and one for the light chain. Protein-based
antibody therapeutics have been exploited in different branches of
biomedical research. However, a wider implementation of protein-
based antibodies is hampered by the high production cost and need
for extensive purification processes. Alternative ways are now being
explored, with mRNA coding for antibodies most recently emerging
as a new genetic approach to deliver antibodies in vivo.11–14 The main
advantage of using mRNA encoding antibodies instead of the protein
format is that the production of antibodies occurs in the body itself,
for a prolonged period of time possibly in a cost-effective manner.
We were able to detect bi-specific protein levels up to 48 h after instil-
lation of mRNA encoding these bi-specific VHH’s in the BAL fluid.
To the contrary, De Vlieger et al.16 could detect bi-specific VHHs un-
til maximum 24 h after protein instillation.
For applications in vivo, specific formulation of mRNA is key. A num-
ber of nanoparticle carriers34,35 have been proposed to increase the
delivery efficiency of mRNA, protecting the mRNA against degrada-
tion by ubiquitous RNases and assisting in transfection of the in-
tended target cells.36,37 Here, mRNA encoding bi-specific VHH
fusion proteins were formulated into DOTAP/cholesterol particles.26
Through i.t. instillation of mRNA-DOTAP/cholesterol particles, the
bi-specific VHH fusion proteins were in situ produced in the lungs,
with a detectable presence of the therapeutic protein for at least
2 days. Previous reports5,38 have shown that systemic delivery of
mRNA nanoparticles composed of cationic lipids, such as DOTAP
or 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA),
can result in mRNA expression levels in the lungs and spleen. In two
studies by Kranz et al.5 and Rosigkeit et al.,38 it was demonstrated that
the organ selectivity between these organs depends on the particle
surface charge and the helper lipid, with cationic mRNA lipoplexes
composed with cholesterol holding a higher transfection efficiency
in the lungs. Furthermore, they showed that this formulation was
able to reach deep lung structures after intravenous (i.v.) administra-
tion, targeting endothelial cells, and epithelial cells, as well as lung-
resident macrophages and dendritic cells. In our study, changingthe administration of the mRNA nanoparticles toward a pulmonary
delivery route resulted in a specific cell targeting of alveolar macro-
phages and successful mRNA transfection in these cells.
With respect to the safety of this delivery approach, we observed that
i.t. instillation of DOTAP/cholesterol mRNA nanoparticles resulted
in a temporary influx of granulocytes in the lungs, combined with
an increase in serum IL-6 cytokine levels. Importantly, these values
were normalized within 24 h after administration. Furthermore, no
other changes in levels of immune cells, nor increases in cytokine
or chemokine levels, were observed. It should be noted that several
steps could be taken that can potentially further improve the safety
profile of the mRNA nanoparticles. The design and production of
the nucleotide-modified mRNA construct can be fully optimized to
eliminate innate immune activation to mRNA, for example by imple-
menting more extensive purification methods for the removal of con-
taminants of double-stranded RNA (dsRNA) fragments. With respect
to the immunotoxicity of lipid nanoparticles, this has been mainly
attributed to their cationic nature.39,40 Therefore, more clinically-
advanced lipid formulations make use of a new generation of cationic
lipids, referred to as ionizable aminolipids.41,42 The acid dissociation
constant (pKa) of these ionizable lipids gives them properties that
allow them to form more stable complexes with mRNA at acidic
pH, while potential “undesirable” immune-related events to the lipid
formulation can be avoided, given their neutral charge at physiolog-
ical pH.
In a prophylactic setting, we showed that a single shot of RiboBiFEs
4 h before challenge with 2 LD50 of A/X47 (H3N2) influenza vi-
rus, protects mice from body weight loss and lethality caused by the
influenza virus infection. Even more, the protection was mediated
by FcgRIV engagement. The treatment described here can be seen
as a disease-modulating treatment, meaning that the prophylactic
treatment will not completely prevent infection but will induce an
earlier clearance of the virus and therefore lower the morbidity. A
potential advantage of this disease-modulating treatment includes
that a moderate infection will take place and can prime an immune
response against the viral pathogen. As a consequence, the immune
system can act more effectively when a viral re-infection takes place.
A disease-modulating treatment is an interesting option for people,
which are at high risk of infection. By giving a single shot of the Ri-
BoBiFEs to this population, it might be possible to reduce the over-
all morbidity and the magnitude of the primary infection.
Compared to a conventional influenza vaccination, the provided
protection would be provided almost instantaneously and would
be more transient.MATERIALS AND METHODS
Cell Lines and Culture Conditions
Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% of fetal calf serum, 2 mM of L-glutamine,
0.4 mM of Na-pyruvate, non-essential amino acids, 100 U/mL of
penicillin, and 0.1 mg/mL of streptomycin at 37C in a humidifiedMolecular Therapy: Nucleic Acids Vol. 20 June 2020 783
Molecular Therapy: Nucleic Acidsatmosphere containing 5% CO2. No full authentication was per-
formed. Cells were tested negative for mycoplasma.
Mice
All experiments were approved by and performed according to the
guidelines of the animal ethical committee of Ghent University
(Ethical application EC2017-092 and ECD 18/64). Female BALB/c
mice aged 7–10 weeks were obtained from Charles River and
FcgRIV/ C57BL/6 mice were bred in-house. All animals were
housed under specified pathogen-free conditions with food and water
ad libitum and a 12/12-h light/dark cycle.
mRNA
The coding information for the BiFE constructs were cloned into a
pUC-plasmid vector containing a T7 promoter, 50 and 30 UTR of
human b globulin, and a poly(A) tail. The plasmids were linearized
with PstI (New England Biolabs, MA, USA) and purified using a
PCR purification kit (Roche, Upper Bavaria, Germany). mRNA
was produced with the T7 mMessage Machine Kit (Ambion, Austin,
TX, USA) according to the manufacturer’s instruction. N1-methyl-
pseudouridine (TriLink, San Diego, CA, USA) was used in the tran-
scription reactions instead of uridine. The in vitro transcribed
mRNA was purified by lithium chloride precipitation and subse-
quently simultaneously capped and 20-O-methylated to synthesize
Cap 1 RNA from uncapped RNA using the ScriptCap m7G Capping
System Kit together with the ScriptCap 20-O-methyltransferase Kit
(Ambion, Austin, TX, USA) according to the manufacturer’s in-
struction. The capped in vitro transcribed mRNA was purified by
lithium chloride precipitation. The mRNA constructs encoding for
firefly luciferase or the fluorescent mCherry protein were purchased
from TriLink (San Diego, CA, USA). These mRNAs are modified
with 5-methoxyuridine, polyadenylated, and capped using a Clean-
Cap method.
mRNA Nanoparticle Preparation
The lipid-based nanoparticles composed with DOTAP and choles-
terol were produced as described by Verbeke et al.26 Lipids were
purchased from Avanti Polar Lipids (Alabaster, AL, USA). Cationic
liposomes of DOTAP/cholesterol (2:3 molar ratio) were prepared by
transferring the appropriate amounts of lipids, dissolved in chloro-
form, into a round-bottom flask. For the cellular uptake study, 1
mol% of the total lipid amount was replaced by the lipophilic DiR
fluorescent dye (Thermo Fisher Scientific). The chloroform was
evaporated under nitrogen, after which the lipid film was rehydrated
in HEPES buffer (20 mM, pH 7.4, Sigma-Aldrich) to obtain a final
lipid concentration of 12.5 mM. The resulting cationic liposomes
were sonicated in a bath sonicator (Branson Ultrasonics, Danbury,
CT, USA). Next, liposomes were mixed with mRNA to obtain
mRNA nanoparticles at a cationic lipid-to-mRNA (N/P) ratio of
3. mRNA nanoparticles for in vivo use were prepared in an isotonic
HEPES buffer containing 5% glucose (Sigma-Aldrich). mRNA lipo-
plexes were subjected to a size quality control via Nanoparticle
Tracking Analysis using the NanoSight LM10 (Malvern, Worcester-
shire, UK). These measurements were performed after incubating784 Molecular Therapy: Nucleic Acids Vol. 20 June 2020the mRNA lipoplexes for 1 h at 37C in either HEPES buffer or mu-
rine BALF. The murine BALF was collected by the protocol
described by Van Hoecke et al.43
In Vitro Transfection
HEK293T cells were plated 24 h before transfection in a 6-well plate at
a density of 106 cells/well. The following day, cells were transfected
with 5 mg of mRNA complexed with Lipofectamine RNAiMAX
(Life Technologies, Ghent, Belgium) diluted in OptiMem to obtain
a total volume of 300 mL. The transfection mix was added to the cells
and cells were incubated at 37C, 5% of CO2 during a time period
of 48 h.
Western Blot
Supernatant of cells transfected with themRNA constructs were sepa-
rated by SDS-PAGE (15% acrylamide) under non-reducing condi-
tions and His-tagged FcgRIV VHH-RSVF VHH and His-tagged
FcgRIV VHH-M2e VHH protein were visualized by western blotting
using anti-His (1,000 dilution; Bio-rad Abd Serotec, Cat. No.
MCA1396) antibodies.
ELISA
M2e-peptide ELISA was performed as described by De Filette
et al.44 Briefly, maxisorp 96-well microtiter plates (Thermo Fisher
Scientific) were coated overnight with 100 ng M2e peptide
(SLLTEVETPIRNEWGCRCNDSSD, corresponding to M2e of hu-
man H3N2 viruses) diluted in 0.1 M carbonate-bicarbonate buffer,
pH 9.6. After overnight coating, wells were washed and blocked
with 5% milk powder in phosphate buffered saline (PBS). Next, dilu-
tion series of the solution containing the VHHs (BALF or supernatant
of cell culture) were added to the wells and incubated for 90 min. The
bound VHHs were detected with mouse anti-histidine tag antibody
(MCA1396, Abd Serotec) and horseradish peroxidase (HRP)-linked
anti-mouse IgG (NXA931, GE Healthcare). Detection was done by
adding 50 mL of TMB (Tetramethylbenzidine, BD OptETA) to every
well; reactions were stopped by addition of 50 mL of 1M H2SO4. The
absorbance was measured at 450 nm with an iMark Microplate
Absorbance Reader (Bio Rad) using 655 nm as background
measurement.
In Vivo Expression and Distribution of mRNA Nanoparticles
Mice were anesthetized with isoflurane/air (Ecuphar, Oostkamp,
Belgium) and i.t. instilled with mRNA DOTAP/cholesterol nanopar-
ticles containing a dose of 5mgmRNA (volume of 50mL). For the biolu-
minescence imaging experiment, mRNA nanoparticles containing
firefly luciferase encoding mRNA were used. 6 h after instillation of
the mRNA nanoparticles, VivoGlo Luciferin-substrate (Promega)
was administered intraperitoneally (i.p.) in a volume of 100 mL
(33mg/mL) permouse. After 10min, bioluminescence images were ac-
quired using the IVIS lumina II system (PerkinElmer, Waltham, MA,
USA), and quantitative analysis of the images was performed using the
Living Image software (PerkinElmer). To evaluate the cellular uptake
and cell-specificmRNA translation, we usedmRNAnanoparticles con-
taining the lipophilic DiR dye and mCherry mRNA. The fluorescent
www.moleculartherapy.orgsignals of DiR (nanoparticle uptake) and the expression of mCherry
protein (mRNA translation) were determined on single cell suspen-
sions processed from complete lungs. At the indicated time points,
mice were euthanized with an i.p. injection of 100 mL Nembutal
(Ceva Santé Animale, Libourne, France). The lungs were dissected
and enzymatically dissociated with an enzymatic lung dissociation kit
and gentleMACS dissociater (Miltenyi Biotec, Leiden, the
Netherlands). Single cell suspensions were stained with a LIVE/
DEAD Fixable Aqua dead cell stain (eBioscience) to exclude dead cells
from analysis, incubated with Fc block (CD16/32) to block nonspecific
FcR binding (BD Biosciences, Erembodegem, Belgium), and surface
stained with monoclonal antibodies during 30 min at room tempera-
ture. The antibody panel to define different pulmonary immune sub-
sets, including subsets of macrophages and dendritic cells, consists of
CD45-BV421 (30-F11), CD11c-FITC (HL3), CD11b-PerCP-Cy5.5
(M1/70), CD24-BV711 (M1/69), CD64-APC (X54-5/7.1), and MHC-
II-SB600 (M5/114.15.2) and was adopted from Knight et al.45 After
additional washing steps, the cells were analyzed on a four-laser fortessa
(Becton Dickinson, San Jose, CA, USA), and data were analyzed using
the FlowJo software (Treestar, Woodburn, OR, USA).
Absolute Bispecific Nanobody Titer Measurement
Mice were anesthetized with isoflurane/air (Ecuphar, Oostkamp,
Belgium) and i.t. instilled with mRNA DOTAP/cholesterol nanopar-
ticles containing a dose of 5 mg mRNA (volume of 50 mL) or with
50 mg bispecific FcgRIV VHH-M2e VHH fusion protein. 6, 24, or
48 h after instillation BALF was collected from the mice as described
by Van Hoecke et al.43 An M2e-peptide ELISA was performed on the
BAL fluid as described above.
Cytokine Measurements
Serum was collected 6 or 24 h after i.t. instillation of the mRNA nano-
particles, and samples were stored at80C. A panel of 13 cytokines,
including IL-1a, IL-1b, IL-6, IL-10, IL-12p70, IL-17A, IL-23, IL-27,
monocyte chemoattractant protein 1 (MCP-1), interferon-b (IFN-
b), IFN-g, tumor necrosis factor alpha (TNF-a), and granulocyte-
macrophage colony-stimulating factor (GM-CSF), was quantified us-
ing a multiplex assay according to the manufacturer’s instructions
(LEGENDplex Mouse Inflammation Panel, Biolegend).
Challenge Experiment in Mice with H3N2
Mice were anesthetized with isoflurane and i.t. instilled with mRNA
lipoplexes containing mRNA encoding FcgRIV VHH-M2e VHH at
a dose of 5 mg mRNA. As controls, PBS or nanoparticles formulated
with luciferase mRNA or a FcgRIV VHH-RSVF VHH mRNA
construct were administered. 4 h later, mice were anesthetized using
isoflurane and challenged intranasally with 2 LD50 of A/X47
(H3N2) influenza virus. Body weight loss was monitored for
14 days. When the body weight dropped below 75% of the initial
body weight, mice were euthanized for ethical reasons.
Plaque Assay to Determine the Viral Titer
Complete lungs were harvested on day 6 after infection and homog-
enized in 1 mL of PBS using a sterile metal bead on the Mixer MillMM 200 (Retsch). Next, the lung homogenates were cleared by
centrifuging at 1,000  g for 10 min at 4C. A serial dilution series
of the cleared lung homogenates, made in serum-free DMEM me-
dium, was added to a monolayer of Madin-Darby Canine
Kidney (MDCK) cells in a 6-well plate (1 million cells per well).
1 h later, the cells were overlaid with an equal volume of 1.2% Avicel
RC-591 (FMC Biopolymer) supplemented with 4 mg/mL of L-1-to-
sylamido-2-phenylethyl chloromethyl ketone (TPCK)-treated
trypsin (Sigma). Plates were incubated at 37C in 5% CO2 for
3 days, after which the overlay was removed and cells were fixed
with 4% paraformaldehyde. Viral plaques were stained using conva-
lescent mouse anti-X47 serum followed by HRP-linked anti-mouse
IgG (NXA931, GE Healthcare). After washing, the plaques were
visualized with TrueBlue peroxidase substrate and counted (KPL,
Gaithersburg, MD, USA).
Statistical Analyses
Statistical analyses were performed in GraphPad Prism 8 software.
Statistical significance between survival rates was done by
comparing Kaplan-Meier curves using the log-rank test and Bon-
ferroni correction. Statistical significance between experimental
groups was assessed using a Kruskal-Wallis test or by one-way
ANOVA followed by Tukey’s post hoc test, as indicated in the
figure captions.
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